Corcept’s relacorilant trial in patients with platinum-resistant ovarian cancer meets primary endpoint
Ella Day | April 1, 2025 | News story | Research and Development | Corcept Therapeutics, Oncology, ovarian cancer, research and development
Corcept Therapeutics announced that relacorilant plus nab-paclitaxel met its primary endpoint of improved progression-free survival in ROSELLA, the company’s phase 3 trial of the therapy.
The ROSELLA trial enrolled 381 patients with platinum-resistant ovarian cancer across sites internationally. Patients were randomised 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. ROSELLA has dual primary endpoints – progression-free-survival (PFS), blinded independent central review (BICR) and overall survival (OS). A positive outcome is achieved if either endpoint is met. The complete results from ROSELLA will be presented at a medical ovarian conference this year.
Corcept Therapeutics is a healthcare company which specialises in developing treatments for severe endocrinologic, oncologic, metabolite and neurological disorders. It does this by modulating the effects of the hormone cortisol.
Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not other hormone receptors. In addition to studying ovarian cancer, Corcept is researching relacorilant in a variety of serious disorders such as prostate cancer.
Ovarian cancer is the fifth most common cause of cancer death in women. Specifically, patients whose disease returns less than six months after receiving platinum-containing therapy have “platinum-resistant” disease (PROC). There are a limited number of treatments available for these women.
Alexander Olawaiye, director of gynaecological cancer research at Magee-Women’s Hospital of the University of Pittsburgh and principal investigator in the ROSELLA trial, said: “Patients with advanced ovarian cancer have few good treatment options and, unfortunately, patients with recurrent disease eventually develop resistance to available therapies. The ROSELLA results represent an important advancement in the development of a treatment for patients with platinum-resistant ovarian cancer.”
Also, Bill Guyer, Corcept’s chief development officer, commented: “The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with PROC.”
Ella Day
1/4/2025
Related Content
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
PlasmidFactory founder Dr. Martin Schleef honoured with the NRW Innovation Award 2025
The founder and long-standing CEO of PlasmidFactory, Dr. Martin Schleef, was honoured in Düsseldorf with …
Corcept reports survival benefit in ALS trial of dazucorilant despite missing primary endpoint
Corcept Therapeutics has announced results from its phase 2 DAZALS study investigating dazucorilant in patients …
